As a monoclonal antibody to vascular endothelial growth factor A, bevacizumab presents a therapy challenging this mechanism by reducing tumor angiogenesis, thus increasing proper perfusion, and lowering hypoxia and therefore radioresistance [165]. The gene discussed is VEGFA; the disease is neoplasm.